Drug intelligence / Profile preview

Ershu Tianma Granules

Development stage: Unknown
Lead developer: PegBio
Administration: Oral

Overview

Ershu Tianma Granules is a Traditional Chinese Medicine (TCM) preparation primarily used to treat dizziness and headaches associated with wind-phlegm internal obstruction. The formula typically consists of *Atractylodis Rhizoma* (Cangzhu), *Atractylodis Macrocephalae Rhizoma* (Baizhu), *Gastrodiae Rhizoma* (Tianma), *Poria* (Fuling), *Citri Reticulatae Pericarpium* (Chenpi), *Pinelliae Rhizoma* (Banxia), and *Glycyrrhizae Radix et Rhizoma* (Gancao). It functions by drying dampness, resolving phlegm, and extinguishing internal wind to alleviate symptoms such as vertigo, chest congestion, and nausea. It is manufactured by companies such as Guizhou Bailing Group Pharmaceutical and is approved by the NMPA in China.

Brand names: Ershu Tianma Granules
Other names: Ershu Tianma Keli二术天麻颗粒

Beyond the preview

Go deeper on Ershu Tianma Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ershu Tianma Granules.

Explore the full profile